AcelRx Pharmaceuticals. has been granted a patent for a dispensing device designed for oral transmucosal drug delivery. The device features a single dose applicator or an electromechanical system with patient identification capabilities and a lock-out feature, enhancing safety and precision in medication administration. GlobalData’s report on AcelRx Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AcelRx Pharmaceuticals, Smart medication dispenser was a key innovation area identified from patents. AcelRx Pharmaceuticals's grant share as of July 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Oral transmucosal drug delivery device and system
The patent US12033733B2 describes an innovative apparatus designed for the delivery of drug-containing tablets, specifically targeting sub-lingual administration. The apparatus features a housing that defines an actuation pathway and a channel, with a delivery member positioned within the actuation pathway. This delivery member is engineered to move distally to expel a drug-containing tablet, which is contained in a volume defined by the distal ends of both the delivery member and the housing. The design includes mechanisms to limit the movement of the delivery member in both proximal and distal directions, ensuring controlled expulsion of the tablet. Notably, the housing incorporates a bridge that can separate from the housing during the actuation process, facilitating the delivery of the drug.
Additionally, the apparatus includes safety features, such as a removable safety member that prevents premature movement of the delivery member. The distal end of the delivery member is designed with a concave portion and a sloped surface, which aids in the deformation of the housing to create an opening for tablet expulsion. The patent specifies that the drug-containing tablet can include sufentanil in various dosages, ranging from 5 mcg to 100 mcg, with the tablet's volume and mass being less than 30 microliters and 30 mg, respectively. This design aims to enhance the efficiency and safety of drug delivery, particularly for medications requiring rapid absorption through the mucosal membrane.
To know more about GlobalData’s detailed insights on AcelRx Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
